• MSc in Computing Science 2000
• PhD in Plant Molecular Biology 1997 
• MSc in Botany 1984 
• BSc in Botany 1982

Wenbin Wei studied for a BSc (1982) and an MSc (1984) in the Department of Biology of Nanjing University. He lectured at Nanjing Normal University between 1985 and 1988. He then worked and studied for a PhD at Leicester University until 1996. After that, he worked at Durham University as a research associate until 1999. He studied for an MSc in Computing Sciences (2000) at the University of Newcastle and then worked as a software engineer for two years initially at Foster Findlay Associates Ltd and then at Nonlinear Dynamics Ltd. He has been a bioinformatician at the University of Birmingham since 2003.

Wenbin Wei is interested in supervising doctoral research students in the following areas:

• Application of Bioinformatics and Biostatics to the omics-driven cancer research
• Development of databases and software tools for cancer research

If you are interesting in studying any of these subject areas please contact Wenbin Wei on the contact details above, or for any general doctoral research enquiries, please email: dr@contacts.bham.ac.uk or call +44 (0)121 414 5005.

For a full list of available Doctoral Research opportunities, please visit our Doctoral Research programme listings.

Research Themes

• Cancer Cell Biology 
• Cancer Genetics 
• Viral Oncology 
• Tumour Immunology 
• Structural Biology & Biomarkers 
• Cancer Prevention, Screening, Diagnosis & Survivorship

Research Activity

Wenbin Wei is interested in collaborative research, especially the application of bioinformatics and biostatistics to the omics-driven cancer research, such as viral oncology, cancer biomarker discovery and evaluation, cancer pathogenesis, cancer genetics and epigenetics, and drug development. He analyzes large amount of genetic, epigenetic, transcriptomic and proteomic data obtained using microarray, mass spectrometry and next generation sequencing. He is also interested in the development of new software tools and databases.

He advises collaborators on experimental design and analysis of new experimental data as well as the mining of existing data in public domain. He does both low level and high level analyses. Low level analyses involve data quality assessment, background subtraction and normalization. High level analyses involve the identification of biomarkers (differentially expressed genes and proteins, hyper- and hypo- methylated genomic regions, point mutations, indels and copy number variation) and the classification of patient samples using supervised and unsupervised analyses, such as logistic regression, hierarchical clustering, principle component analysis, partial least square analysis and neural network. He also does survival analysis and provides advice on gene ontology analysis and promoter analysis.

Automated Pub Med Search for Dr. Wenbin Wei|

Bryan, R., W. Wei, N. J. Shimwell, S. Collins, S. A. Hussain, L. J. Billingham, P. Murray, N. Deshmukh, N. James, M. Wallace, P. J. Johnson, M. P. Zeegers, K. Cheng, A. Martin and D. G. Ward (2011). "Assessment of High-Throughput High-Resolution MALDI-TOF-MS of Urinary Peptides for the Detection of Muscle-Invasive Bladder Cancer." Proteom Clin Appl 5(9-10):493-503.

Leonard, S., W. Wei, J. Anderton, M. Vockerodt, M. Rowe, P. G. Murray and C. B. Woodman (2011). "Epigenetic and Transcriptional Changes Which Follow Epstein-Barr Virus Infection of Germinal Center B Cells and Their Relevance to the Pathogenesis of Hodgkin's Lymphoma." J Virol 85(18): 9568-9577.

Vrzalikova, K., M. Vockerodt, S. Leonard, A. Bell, W. Wei, A. Schrader, K. L. Wright, D. Kube, M. Rowe, C. B. Woodman and P. G. Murray (2011). "Down-regulation of BLIMP1{alpha} by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas." Blood 117(22): 5907-5917.

Voss, M. A., N. Gordon, S. Maloney, R. Ganesan, L. Ludeman, K. McCarthy, R. Gornall, G. Schaller, W. Wei, F. Berditchevski and S. Sundar (2011). "Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer." Br J Cancer 104(10): 1611-1618.

Leong, K. J., W. Wei, L. A. Tannahill, G. M. Caldwell, C. E. Jones, D. G. Morton, G. M. Matthews and S. P. Bach (2011). "Methylation profiling of rectal cancer identifies novel markers of early-stage disease." Br J Surg 98(5): 724-34.

Shuib, S., W. Wei, H. Sur, M. R. Morris, D. McMullan, E. Rattenberry, E. Meyer, P. H. Maxwell, T. Kishida, M. Yao, F. Latif and E. R. Maher (2011). "Copy number profiling in von hippel-lindau disease renal cell carcinoma." Genes Chromosomes Cancer 50(7): 479-488.

Anderton, J. A., S. Bose, M. Vockerodt, K. Vrzalikova, W. Wei, M. Kuo, K. Helin, J. Christensen, M. Rowe, P. G. Murray and C. B. Woodman (2011). "The H3K27me3 demethylase, KDM6B, is induced by Epstein-Barr virus and over-expressed in Hodgkin's Lymphoma." Oncogene 30(17): 2037-2043.

Lim, K. P., N. Cirillo, Y. Hassona, W. Wei, J. K. Thurlow, S. C. Cheong, G. Pitiyage, E. K. Parkinson and S. S. Prime (2011). "Fibroblast gene expression profile reflects the stage of tumour progression in oral squamous cell carcinoma." J Pathol 223: 459-469.

Lu, X., W. Wei, J. Fenton, M. S. Nahorski, E. Rabai, A. Reiman, L. Seabra, Z. Nagy, F. Latif and E. R. Maher (2011). "Therapeutic targeting the loss of the birt-hogg-dube suppressor gene." Mol Cancer Ther 10(1): 80-9.

Shimwell, N. J., W. Wei, S. Wilson, M. J. Wakelam, T. Ismail, T. Iqbal, P. J. Johnson, A. Martin and D. G. Ward (2010). "Assessment of novel combinations of biomarkers for the detection of colorectal cancer." Cancer Biomark 7(3): 123-32.

Murray, P. G., Y. Fan, G. Davies, J. Ying, H. Geng, K. M. Ng, H. Li, Z. Gao, W. Wei, S. Bose, J. Anderton, G. Kapatai, G. Reynolds, A. Ito, T. Marafioti, C. B. Woodman, R. Ambinder and Q. Tao (2010). "Epigenetic Silencing of a Proapoptotic Cell Adhesion Molecule, the Immunoglobulin Superfamily Member IGSF4, by Promoter CpG Methylation Protects Hodgkin Lymphoma Cells from Apoptosis." Am J Pathol 177: 1480-1490.